Pharmaceutical News

RSS

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

7 May 2010

Town hall meeting to address negative health, societal consequences of methamphetamine abuse

Pan American Bank (Los Angeles) today announced that it has partnered with the UCLA Youth Methamphetamine Treatment Study, LatinoGraduate.net and The Wall-Las Memorias Project to host a town hall meeting that addresses the negative health and societal consequences of methamphetamine abuse by Latino youth.

7 May 2010

Intellipharmaceutics generic Effexor XR ANDA accepted for filing by the FDA

Intellipharmaceutics International Inc., today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of the antidepressant Effexor XR® (venlafaxine hydrochloride).

7 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

Meda acquires exclusive rights for use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals

Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.

7 May 2010

Progestins increase chances of cancer metastasizing: Study

After menopause, 6 to 10 million women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries. Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus. In studies sponsored by the National Institutes of Health, evidence has been found that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.

7 May 2010

Merrion Pharmaceuticals increases patent protection for Orazol

Merrion Pharmaceuticals plc, a pharmaceutical development company, today announces that it has been granted a further U.S. Patent, increasing the protection for their lead product, Orazol™.

7 May 2010

Judge's ruling gives 'wide latitude' to plaintiffs' in lawsuits against Omniscan imaging drug

ProPublica: In a key ruling, "a federal judge has given plaintiffs' lawyers wide latitude to present evidence and expert testimony that GE's Omniscan imaging drug caused a crippling disease in MRI patients."

7 May 2010

Natazia tablets receive FDA approval for prevention of pregnancy

Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.

7 May 2010

The Forum calls upon pharma suppliers, distributors, pharmacies to stop distribution of unapproved drugs

Gary Puckrein, President and CEO of the National Minority Quality Forum (The Forum), recently sent a letter to the CEOs of eight major pharmaceutical suppliers, distributors and pharmacies to educate them on the potential threats posed by unapproved drugs in the United States and to ask that they do their part to protect consumers from the harms that can be caused by these unproven products.

7 May 2010

Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.

7 May 2010

$DMPA injectible contraceptive associated with increased risk of bone fracture$

DMPA injectible contraceptive associated with increased risk of bone fracture

A new study presented today at the World Congress on Osteoporosis (IOF WCO-ECCEO10) in Florence, Italy shows that DMPA, a commonly used injectible contraceptive, is associated with higher risk of bone fracture when used alone, and not in combination with estrogens.

7 May 2010

FDA approves new oral contraceptive Natazia

The U.S. Food and Drug Administration today approved Natazia, a combination hormonal tablet for use as an oral contraceptive.

7 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

SCOLR Pharma, Inc. today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation, (RedHill), granting RedHill the worldwide rights to market and sell ondansetron tablet formulations based on SCOLR's proprietary extended delivery technology (CDT). Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline's drug to prevent chemotherapy and radiation related nausea and vomiting.

6 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

Columbia Laboratories reports 34% increase in net revenues from U.S. sales of progesterone products

Columbia Laboratories, Inc. today announced financial results for the three-month period ended March 31, 2010.

6 May 2010

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

6 May 2010

CombinatoRx reports $41.3M total revenue for first-quarter 2010

CombinatoRx, Incorporated today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

Scientists at the University of Pittsburgh School of Medicine went on a molecular fishing trip and netted a catch of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes. Their findings were published today in the online version of Nature Chemical Biology.

6 May 2010

Pharmaceutical News

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

Town hall meeting to address negative health, societal consequences of methamphetamine abuse

Intellipharmaceutics generic Effexor XR ANDA accepted for filing by the FDA

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

Meda acquires exclusive rights for use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals

Progestins increase chances of cancer metastasizing: Study

Merrion Pharmaceuticals increases patent protection for Orazol

Judge's ruling gives 'wide latitude' to plaintiffs' in lawsuits against Omniscan imaging drug

Natazia tablets receive FDA approval for prevention of pregnancy

The Forum calls upon pharma suppliers, distributors, pharmacies to stop distribution of unapproved drugs

Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

DMPA injectible contraceptive associated with increased risk of bone fracture

FDA approves new oral contraceptive Natazia

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Columbia Laboratories reports 34% increase in net revenues from U.S. sales of progesterone products

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

CombinatoRx reports $41.3M total revenue for first-quarter 2010

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News